Poly(pro-drug) Material Sustained Estrogen Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering estrogen for extended periods in medical applications, such as spinal cord injuries, are limited by short release durations and require frequent replacements or carrier polymers, which are not ideal for long-term therapeutic efficacy.
Innovation Solution
A poly(pro-drug) material comprising polymers with therapeutic compounds like estrogen, curcumin, or fingolimod, linked via cleavable ester, urethane, or carbonate groups, and biodegradable hydrocarbyl chains, allowing for controlled release rates of 0.01-0.25% per day at physiological conditions, enabling prolonged therapeutic effects without the need for frequent replacements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If polymeric nanospheres are used for estrogen delivery, then release duration is extended to 8 days, but the device requires co-loading with albumin and still needs frequent replacement
Solution Approach 1:
The patent uses polymeric nanospheres composed of biodegradable polymers (PLA, PLGA, or PCL) as a composite material system to deliver estrogen. The nanospheres incorporate estrogen directly into the polymer matrix, eliminating the need for co-loading with albumin while achieving extended release durations of several months through controlled polymer degradation
Solution Approach 2:
The patent extends estrogen release duration by changing the polymer degradation parameters - using polymers with controlled molecular weights, lactide:glycolide ratios, and crystallinity to achieve sustained release over several months rather than days, thereby reducing replacement frequency
2Reliability
If estrogen is delivered orally using drugs like Premarin or Menest, then therapeutic effects are achieved, but frequent administration is required due to short half-life
Solution Approach 1:
The patent employs a preliminary action by pre-implanting estrogen-loaded polymeric nanospheres into the target tissue, where they gradually release estrogen over several months. This eliminates the need for repeated oral administrations, as the implant provides sustained therapeutic levels continuously
Solution Approach 2:
The patent replaces the mechanical/oral administration system with a植入式 (implantable) delivery system that uses polymer degradation mechanics to control drug release, substituting frequent manual dosing with a single implantation event followed by passive, controlled release
3Duration of action of moving object
If Estradurin oligomeric pro-drug is used for estrogen delivery, then extended release is achieved, but the product is discontinued and has limited availability
Solution Approach 1:
The patent segments the estrogen molecule by converting it into an ester pro-drug form (e.g., estradiol valerate, estradiol cypionate) attached to biodegradable polymer chains. This segmentation allows the estrogen to be released gradually as the polymer degrades, achieving extended duration while using commercially available polymer materials
Solution Approach 2:
The patent creates a universal polymeric nanosphere platform that can deliver estrogen or other therapeutic agents through the same mechanism. The platform uses commercially available biodegradable polymers (PLA, PLGA, PCL) that can be manufactured using standard techniques, ensuring ease of production and availability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The poly(pro-drug) material provides sustained release of therapeutic compounds over several months to years, enhancing therapeutic efficacy and reducing the frequency of device replacement, with demonstrated benefits in promoting neurite outgrowth and tissue regeneration.
Implementation Method 1
The polymers are relatively ill-defined short oligomers with extensive chain branching. The average number of estrogen molecules in one Estradurin® oligomer is approximately 13. Estradurin® is currently discontinued in the United States.
Implementation Method 2
In some embodiments, the biodegradable hydrocarbyl group includes poly(ethylene glycol), poly(ethylene glycol) dithiol, or combinations thereof
Data Source
AI summary
The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself. In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile. Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient. These materials are enticing for a myriad of biomedical applications, including veterinary medicine, cancer treatments, birth control, and hormone replacement therapy.